Analysts' recommendations: Alzinova AB

06-24	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
04-08	RX Securities sees potential upside for Alzinova from Alzheimer's diagnostic collaboration	FW
03-26	DNB Carnegie sees reduced financing risk for Alzinova, but partnership remains critical	FW
25-10-06	Alzinova gets fast track designation from US FDA	RE
25-10-05	Alzinova's Alzheimer's Disease Vaccine Candidate Gets Fast-track Designation from US FDA	MT

More recommendations

Managers and Directors: Alzinova AB

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	2024-09-30
Anders Sandberg COO	Chief Operating Officer	54	2011-08-16
Erik Kullgren DFI	Director of Finance/CFO	57	2024-03-26

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	2015-08-31
Anders Waas BRD	Director/Board Member	69	2017-12-31
Carol Routledge BRD	Director/Board Member	-	2017-12-31

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	-4.81%	-9.17%	-70.14%	-84.03%	8.34M
LONZA GROUP AG	+1.70%	+7.41%	+3.12%	+8.46%	49.15B
REVOLUTION MEDICINES, INC.	+0.92%	+3.93%	+399.71%	+605.33%	40.23B
IQVIA HOLDINGS INC.	+1.89%	+8.32%	+26.06%	-6.35%	34.55B
BEONE MEDICINES AG	+2.38%	+6.35%	+21.25%	+64.58%	33.09B
CELLTRION, INC.	+3.96%	+10.67%	+11.89%	+38.86%	25.19B
ASCENDIS PHARMA A/S	+2.51%	+5.27%	-	-	17.05B
MEDPACE HOLDINGS, INC.	+2.58%	+5.79%	+73.44%	+133.27%	15.92B
EUROFINS SCIENTIFIC SE	+0.32%	+0.58%	+13.67%	+19.09%	13.83B
IONIS PHARMACEUTICALS, INC.	+3.30%	+0.76%	+90.23%	+99.12%	13.52B
Average	+1.48%	+4.61%	+63.25%	+97.59%	24.25B
Weighted average by Cap.	+2.05%	+6.10%	+91.87%	+139.21%

See all sector performances

Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-07-03	SEK 0.4950	-4.81%	1,057,323
26-07-02	SEK 0.5200	-1.52%	1,808,347
26-07-01	SEK 0.5280	+6.45%	4,211,288
26-06-30	SEK 0.4960	-7.98%	1,595,991
26-06-29	SEK 0.5390	-1.10%	295,075

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2026-07-03 EDT			5-day change	1st Jan Change
0.4950 ^SEK	-4.81%		-9.17%	-40.29%

Market Cap	76.71M 7.95M 6.95M 6.39M 5.96M 11.3M 757M 11.47M 29.82M 372M 29.85M 29.21M 1.28B	P/E 2026 *	-1.83x	P/E 2027 *	-1.3x
Enterprise Value	60.71M 6.29M 5.5M 5.06M 4.71M 8.94M 599M 9.08M 23.6M 295M 23.63M 23.12M 1.02B	EV / Sales 2026 *	1.94x	EV / Sales 2027 *	-
Free-Float	82.23%	Yield 2026 *	-	Yield 2027 *	-

06-24	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test	CI
06-24	Alzinova Inks Nonbinding Deal with Fujirebio for Potential Alzheimer's Blood-based Diagnostic Test	MT
06-24	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
06-24	Alzinova signs non-binding letter of intent with Fujirebio on Alzheimer's diagnostics	FW
06-12	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
06-08	Alzinova raises SEK 15.2 million before issuance costs	FW
05-26	Calendar Tuesday May 26	FW
05-25	Calendar Tuesday May 26	FW
05-21	Alzinova secures 80 percent of TO4 warrants	FW
05-20	Alzinova phase 1b results published in scientific journal	FW
05-20	Alzinova AB Publishes Clinical Results with ALZ-101 in Alzheimer?s Research & Therapy	CI
05-13	Alzinova AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Alzinova Q1 loss after financial items SEK 6 mln	RE

06-24	Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds	AQ
06-24	Alzinova signs Letter of Intent with Fujirebio regarding potential commercialization of blood-based Alzheimer’s diagnostic test	AQ
06-12	Warrants of series TO4 were exercised to approximately 94.2 percent and the Company will receive approximately 15.3 million	AQ
06-08	Alzinova announces preliminary outcome of the exercise of warrants of series TO4	AQ
06-03	The last day of trading with the warrants of series TO4 in Alzinova is today, June 3, 2026	AQ

1 day	-4.81%
1 week	-9.17%
Current month	-0.20%
1 month	+12.50%
3 months	-17.50%
6 months	-41.07%
Current year	-40.29%

Alzinova AB Stock

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Course Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	0.49	0.55
1 month	0.43	0.59
Current year	0.38	0.97
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	9.18
10 years	0.38	44.9

	2026 *	2027 *
Net sales	31.35M 3.25M 2.84M 2.61M 2.43M 4.62M 309M 4.69M 12.19M 152M 12.2M 11.94M 524M	-
Net income	-3.2M -332K -290K -267K -248K -471K -31.59M -478K -1.24M -15.53M -1.25M -1.22M -53.51M	-50.35M -5.22M -4.56M -4.19M -3.91M -7.41M -497M -7.53M -19.57M -244M -19.6M -19.17M -842M
Net Debt	-16M -1.66M -1.45M -1.33M -1.24M -2.36M -158M -2.39M -6.22M -77.64M -6.23M -6.09M -268M	-19M -1.97M -1.72M -1.58M -1.48M -2.8M -188M -2.84M -7.39M -92.2M -7.39M -7.24M -318M